Auvi-Q (epinephrine injection) auto-injector for anaphylaxis to be reintroduced to the US market- Kaléo
Kaléo has announced that it will reintroduce Auvi-Q (epinephrine injection) auto-injector to the U.S. market in the first half of 2017. Auvi-Q is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.
After regaining the rights to Auvi-Q, Kaléo conducted a thorough manufacturing assessment and invested in new technology and quality systems to ensure accurate, reliable and consistent delivery from the product. Auvi-Q is manufactured on an intelligent, high-tech, 100% automated robotic production line with more than 100 automated quality checks on each Auvi-Q, ensuring a streamlined and consistent production process.
Comment: Auvi-Q was withdrawn from the market due to injector faults and Sanofi, licensee of the product, terminated its agreement with Kaléo. The market was dominated by EpiPen from Mylan which has attracted intense criticism from Congress and the public for its savage price increases. Recently Mylan had to settle a claim for overcharging brought by the US Department of Justice. The question is whether the return of Auvi-Q will be result in reasonable prices.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins